88 completed, 11 terminated, 3 unknown, 3 withdrawn. 105 Phase 1, 26 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 105 | Completed 88, Terminated 11, Unknown 3, Withdrawn 3 |
| Phase 2 | 26 | Completed 20, Terminated 4, Unknown 1, Withdrawn 1 |
Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
| Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir Sofosbuvir-Velpatasvir Drug Combination - Hepatitis C, Chronic | Phase 1 | Completed | Catherine Anne Chappell | 11 | 2020-10-22 | 2025-01-01 |
| Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects HEC74647, HEC110114 - Chronic Hepatitis C | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 28 | 2020-07-15 | 2020-11-05 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects HEC74647PA capsule, placebo - Chronic Hepatitis C | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 28 | 2019-12-18 | 2020-03-19 |
| The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects HEC110114 tablet, Placebo Oral Tablet - Chronic Hepatitis C | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 93 | 2019-03-06 | 2020-03-18 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Ain Shams University | 24 | 2019-03-01 | 2023-08-22 |
| The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects HEC74647PA Capsule, placebo - Chronic Hepatitis c | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 105 | 2018-09-04 | 2020-03-19 |
| A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China Ravidasvir 50mg, Ravidasvir 200mg - Chronic Hepatitis c | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 12 | 2018-01-15 | 2018-06-29 |
| The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects Kangdaprevir Sodium Tablet, placebo - Chronic Hepatitis c | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 120 | 2018-01-11 | 2020-03-19 |
| A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients MB-110, Placebo - Chronic Hepatitis C | Phase 1 | Unknown | Microbio Co Ltd | 40 | 2017-12-01 | 2017-04-05 |
| Study of AT-527 in Healthy and HCV-Infected Subjects AT-527, Placebo Comparator - Chronic Hepatitis C, Hepatitis C | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 88 | 2017-07-06 | 2020-02-18 |
| A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) Uprifosbuvir, Ruzasvir - Hepatitis C, Chronic | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2016-01-22 | 2018-09-17 |
| A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers AL-335, ACH-3102, Simeprevir - Chronic Hepatitis C | Phase 1 | Completed | Alios Biopharma Inc. | 32 | 2015-07-31 | 2019-10-16 |
| Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection Autologous DC-vaccines - Hepatitis C, Chronic, Liver Diseases | Phase 1 / Phase 2 | Completed | Russian Academy of Medical Sciences | 10 | 2015-05-01 | 2019-05-10 |
| First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 AL-335 matching placebo, AL-335 - Chronic Hepatitis C | Phase 1 | Completed | Alios Biopharma Inc. | 112 | 2014-12-31 | 2019-10-16 |
| The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects yimitasvir, placebo - Chronic Hepatitis c | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 32 | 2014-12-03 | 2018-03-12 |
| Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C Chlorcyclizine HCl, Ribavirin - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 24 | 2014-03-20 | 2020-06-09 |
| Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects IDX21459, Matching Placebo - Chronic Hepatitis C | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 48 | 2014-03-01 | 2016-01-26 |
Showing 20 of 105. Sign in to see all of them.
Hepatitis C (32) · Liver Diseases (5) · Hepatitis (3) · Virus Diseases (3) · Hepatitis, Viral, Human (2) · Infections (2) · Acquired Immunodeficiency Syndrome (1) · Bronchiolitis Obliterans Syndrome (1) · Flaviviridae Infections (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Hemophilia A (1) · Leukemia (1) · Recurrence (1)
Blood-Borne Infections (105) · Chronic Disease (105) · Communicable Diseases (105) · Digestive System Diseases (105) · Disease Attributes (105) · Hepatitis, Chronic (105) · Pathologic Processes (105) · Pathological Conditions, Signs and Symptoms (105) · RNA Virus Infections (105) · Flaviviridae Infections (104) · Hepatitis, Viral, Human (103) · Infections (103) · Hepatitis (102) · Virus Diseases (102) · Liver Diseases (100)
Ribavirin (14) · Ritonavir (4) · peginterferon alfa-2a (4) · telaprevir (4) · faldaprevir (3) · peginterferon alfa-2b (3) · samatasvir (3) · AT-511 (2) · BID protein, human (2) · GSK2878175 (2) · IDX184 (2) · Simeprevir (2) · Sofosbuvir (2) · adafosbuvir (2) · daclatasvir (2)
Merck Sharp & Dohme LLC (17) · Boehringer Ingelheim (7) · Sunshine Lake Pharma Co., Ltd. (7) · Bristol-Myers Squibb (6) · Hoffmann-La Roche (5) · Alios Biopharma Inc. (4) · Gilead Sciences (4) · GlaxoSmithKline (3) · Tanabe Pharma Corporation (3) · Vertex Pharmaceuticals Incorporated (3) · Atea Pharmaceuticals, Inc. (2) · Bader, Ted, M.D. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Presidio Pharmaceuticals, Inc. (2) · Sandoz (2)
United States (38) · China (8) · France (8) · Puerto Rico (8) · Australia (5) · Canada (5) · Germany (5) · New Zealand (5) · Japan (3) · Moldova (3) · Belgium (2) · Israel (2) · Poland (2) · South Korea (2) · Spain (2)
Yanhua Ding, Doctor (5) · Fumitaka Suzuki, MD (2) · Nathaniel Brown, M.D. (2) · Piyush Patel, M.D. (2) · Alejandro Soza, MD (1) · Aleksandra Pastrak, M.D. (1) · Alexander A Ostanin, MD, PhD (1) · Brian Sanderson (1) · Carin MJ van Nieuwkerk, MD, PhD (1) · Catherine Chappell, MD, MSc (1)
PMID 20938912, PMID 20951424, PMID 21145839, PMID 21354234, PMID 21699798, PMID 22239508, PMID 22414766, PMID 22425702, PMID 23070151, PMID 23190247, PMID 23396509, PMID 23490393, PMID 23872824, PMID 23877706, PMID 24145880, PMID 24295986, PMID 24434503, PMID 24733462, PMID 25385099, PMID 25456558, PMID 25801562, PMID 26183611, PMID 26621580, PMID 26733671, PMID 27137491, PMID 27353271, PMID 29301580, PMID 29638206, PMID 29736243, PMID 30325939, PMID 30350297, PMID 30680407, PMID 31570394, PMID 31868916, PMID 32088322, PMID 34252301, PMID 34307188, PMID 37925363, PMID 39706761
2008 (2), 2009 (1), 2019 (1), R01DK090794 (1), R21AT003892 (1), R21HD101996 (1), R34HL109334 (1)